Close

Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/16/2024

1. SPY
2. TSLA
3. RDDT
4. TCS:IN
5. JPM
6. MSFT
7. C
8. GS
9. ALAB
10. SCHW


Go back to Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 750.77 --0 (-0%)
Previous Close $750.77    52 Week High $88.16 
Open $750.77    52 Week Low $67.88 
Day High $750.77    P/E 173.79 
Day Low $750.77    EPS $4.32 
Volume 476